Zenotech Laboratories Ltd (ZENOTECH) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Zenotech Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Submission of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026.
Outcome · 28 Oct 2026, 7:56 pm
Zenotech Laboratories Reports Widened Net Loss of ₹257.33 Lakh in Q2 FY27 Zenotech Laboratories reported standalone revenue from operations of ₹613.15 lakh for the quarter ended 30th Sep'26, down 40.07% YoY from ₹1,023.19 lakh and down 36.11% QoQ from ₹959.64 lakh. Total income stood at ₹757.15 lakh versus ₹1,193.64 lakh in Q2 FY26. Net loss widened significantly to ₹257.33 lakh compared to a loss of ₹83.65 lakh in Q2 FY26 and a loss of ₹45.55 lakh in Q1 FY27, resulting in an EPS of negative ₹0.42. For H1 FY27, net loss reached ₹302.88 lakh.
Approval for Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026.
Financial Result · 28 Oct 2026, 7:51 pm
Zenotech Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakhs) ■ Revenue: 715 (-36.4% YoY | -32.6% QoQ) ■ EBITDA: -203 (Profit to Loss YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -28.4 (Profit to Loss YoY | Profit to Loss QoQ) ■ PAT: -257 (-207.6% YoY | -464.9% QoQ) ■ EPS (INR): -0.42 (-200.0% YoY | -500.0% QoQ)
Zenotech Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 ,inter alia, to consider and approve Unaudited Standalone ....
Intimation · 28 Oct 2026, 5:30 am
Zenotech Laboratories Schedules Board Meeting on 28th Oct'26 to Consider Q2 Results Zenotech Laboratories Limited announced that its Board of Directors will meet on 28th Oct'26 to consider and approve the unaudited standalone financial results for the quarter and half year ended 30th Sep'26. Additionally, the trading window for dealing in company shares, which has been closed since 1st Oct'26, will remain shut until 48 hours following the declaration of financial results, reopening after 30th Oct'26.
Voting Results and Scrutinizer Report of 37th Annual General Meeting of the Company held on September 25, 2026.
Annual General Meeting · 26 Sept 2026, 5:33 pm
Outcome of the 37th Annual General Meeting of the Company held on Friday, September 25, 2026.
Annual General Meeting · 25 Sept 2026, 8:55 pm
Notice of 37th Annual General Meeting along with Annual Report for the FY 2025-26
Annual General Meeting · 28 Aug 2026, 6:26 pm
Annual Report 2025-26 and the Notice of 37th Annual General Meeting
Others (Uncategorized) · 28 Aug 2026, 6:20 pm
Intimation of 37th Annual General Meeting of the Company to be held on Friday, September 25, 2026 at 10:30 a.m. IST through Video Conferencing mode.
Annual General Meeting · 22 Aug 2026, 11:03 pm
Outcome of the Board Meeting held today, i.e., July 28, 2026
Outcome · 28 Jul 2026, 8:17 pm
Zenotech Laboratories Reports Q1FY27 Loss, Announces AGM Date Zenotech Laboratories posted a net loss of ₹45.55 lakhs for the quarter ended 30th Jun'26, compared to a profit of ₹98.96 lakhs YoY. Revenue from operations grew 11.1% YoY to ₹959.64 lakhs. Total income increased 7.9% YoY to ₹1,104.79 lakhs, while total expenses rose 29.8% YoY to ₹1,164.86 lakhs, driven by higher employee benefit costs. Diluted EPS stood at ₹(0.07) against ₹0.16 YoY. The Board also approved the 37th Annual General Meeting, to be held via videoconference on 25th Sep'26.
Submission of Unaudited Financial Results of the Company for the quarter ended June 30, 2026.
Financial Result · 28 Jul 2026, 8:10 pm
Zenotech Laboratories Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 1,061 (+10.0% YoY | +7.4% QoQ) ■ EBITDA: 86.6 (-64.8% YoY | +403.7% QoQ) ■ EBITDA Margin (%): 8.2 (-1737 bps YoY | +642 bps QoQ) ■ PAT: -45.6 (Profit to Loss YoY | +85.5% QoQ) ■ EPS (INR): -0.07 (Profit to Loss YoY | +86.5% QoQ)
Zenotech Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2026 ,inter alia, to consider and approve Unaudited Standalone ....
Intimation · 28 Jul 2026, 5:30 am
Zenotech Laboratories to Announce Q1 FY27 Results on 28th July Zenotech Laboratories (BSE: 532039) has scheduled a Board of Directors meeting on 28th Jul'26 to consider and approve the Unaudited Standalone Financial Results for the quarter ended 30th Jun'26. In connection with this, the trading window for designated persons has been closed from 01st Jul'26 and will reopen on 31st Jul'26, 48 hours after the results are declared. This meeting is a key event for investors tracking the company's Q1 performance.
Audited Standalone Financial Results for the quarter and financial year ended March 31, 2026 and declaration of unmodified opinion on the Financial Results.
Financial Result · 29 Apr 2026, 9:49 pm
ZENOTECH LABORATORIES LIMITED - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 887 (-20.2% YoY | -25.0% QoQ) ■ EBITDA: 17.2 (-96.2% YoY | -96.0% QoQ) ■ EBITDA Margin (%): 1.9 (-3828 bps YoY | -3412 bps QoQ) ■ PAT: -315 (Profit to Loss YoY | Profit to Loss QoQ) ■ EPS (INR): -0.52 (Profit to Loss YoY | Profit to Loss QoQ)
Submission of Audited Standalone Financial Results for the quarter and financial year ended March 31, 2026
Outcome · 29 Apr 2026, 9:42 pm
ZENOTECH LABORATORIES LIMITED - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakhs) ■ Revenue: 887 (-20.2% YoY | -25.0% QoQ) ■ EBITDA: 17.2 (-96.2% YoY | -96.0% QoQ) ■ EBITDA Margin (%): 1.9 (-3828 bps YoY | -3412 bps QoQ) ■ PAT: -315 (Profit to Loss YoY | Profit to Loss QoQ) ■ EPS (INR): -0.52 (Profit to Loss YoY | Profit to Loss QoQ)
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 28 Apr 2026, 8:32 pm
Zenotech Confirms It Is Not Classified as a Large Corporate Zenotech Laboratories Limited informed exchanges on 28 Apr'26 that it does not qualify as a Large Corporate (LC) under the criteria of SEBI Circular dated 19 Oct'23. Consequently, the company is not required to raise funds through debt securities or comply with the associated disclosure requirements, including filing Annexures A, B1, and B2. This confirms the non-applicability of the mandatory fundraising framework for the company.
Zenotech Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/04/2026 ,inter alia, to consider and approve Audited Standalone Financial ....
Intimation · 29 Apr 2026, 5:30 am
Zenotech Labs Board to Approve Q4 & FY26 Results on Apr 29 Zenotech Laboratories (BSE: 532039) has scheduled a Board of Directors meeting on 29 Apr'26. The agenda includes the consideration and approval of the Audited Standalone Financial Results for the quarter and financial year ended 31 Mar'26. In connection, the trading window for designated persons has been closed from 01 Apr'26 and will reopen on 01 May'26, 48 hours after the results are declared.
Clarification on Price Movement is enclosed herewith
Others (Uncategorized) · 10 Apr 2026, 3:07 pm
Zenotech Laboratories Clarifies Recent Share Price Movement to BSE Zenotech Laboratories (Scrip Code: 532039) responded on 10th Apr'26 to a BSE inquiry regarding a significant, recent movement in its stock price. The company confirmed it is in full compliance with SEBI (LODR) Regulations, 2015. Zenotech stated it has not withheld any material information or impending announcements that could explain the share price volatility. Management asserts that all price-sensitive information has been properly disclosed, attributing no specific corporate event to the recent market activity.
The Exchange has sought clarification from Zenotech Laboratories Ltd on April 9, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 10 Apr 2026, 2:15 pm
Outcome of the Board Meeting held today, i.e., January 23, 2026
Outcome · 23 Jan 2026, 9:54 pm
Zenotech Board Approves Q3FY26 Results, New Director, and Committee Changes Zenotech Laboratories reported Q3FY26 standalone results, with revenue from operations at ₹1,182.60 lakhs, up 15.6% YoY and 15.6% QoQ. Profit after tax stood at ₹192.56 lakhs, up 13.7% YoY. The board approved the appointment of Mr. Nikkhil Venilal Kothhari as an Additional Independent Director for five years, effective 23 Jan'26. It also noted the cessation of Mr. Chintan Jitendra Shah as Independent Director from 26 Jan'26 and reconstituted its Audit, Nomination & Remuneration, and Stakeholders Relationship Committees, effective 27 Jan'26.
Unaudited Financial Results for the quarter and nine months ended December 31, 2025
Financial Result · 23 Jan 2026, 9:49 pm
Zenotech Board Approves Q3FY26 Results and Director Changes Zenotech Laboratories' board approved Q3FY26 results, appointing Mr. Nikkhil Venilal Kothhari as Additional Independent Director from 23 Jan'26. Q3FY26 PAT was ₹192.56 lakhs vs. ₹169.28 lakhs YoY. Total income grew 14.3% YoY to ₹1,327.75 lakhs. Mr. Chintan Jitendra Shah's tenure as Independent Director will end on 26 Jan'26. The board also approved the reconstitution of its Audit, Nomination & Remuneration, and Stakeholders Relationship Committees, effective 27 Jan'26.
Zenotech Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2026 ,inter alia, to consider and approve Unaudited Standalone ....
Intimation · 23 Jan 2026, 5:30 am
Zenotech Laboratories Board Meeting Scheduled for Q3 FY26 Results Zenotech Laboratories will hold a Board Meeting on 23 Jan'26 to consider and approve its Unaudited Standalone Financial Results for the quarter and nine months ended 31 Dec'25. In connection with this, the company's trading window has been closed from 01 Jan'26 and will reopen on 26 Jan'26, 48 hours after the results are declared.
Approval of Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2025.
Outcome · 31 Oct 2025, 11:37 pm
Approval of Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2025
Financial Result · 31 Oct 2025, 11:32 pm
Zenotech Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2025 ,inter alia, to consider and approve Unaudited Standalone ....
Intimation · 31 Oct 2025, 5:30 am
We wish to inform that the members of Zenotech Laboratories Limited, at the 36th Annual General Meeting held on September 26, 2025, inter-alia, have considered and approved the Appointment ....
Change in Auditor · 30 Sept 2025, 12:28 am
Disclosure of Voting Results and Scrutinizer''s Report dated September 29, 2025.
Annual General Meeting · 29 Sept 2025, 11:08 pm